Samsung Bioepis has announced US Food and Drug Administration (FDA) approval for PYZCHIVA (ustekinumab-ttwe / SB17) as a biosimilar to Stelara (ustekinumab). The approval includes subcutaneous ...

(RTTNews) - Sandoz Group AG (SDZNY.OB), a Swiss company that focuses on generic pharmaceuticals and biosimilars, today announced the approval of Pyzchiva. The FDA has granted approval to Pyzchiva, a ...

(RTTNews) - Sandoz Group AG (SDZNY), a Swiss maker of generic and biosimilar medicines, announced Monday that the US Food and Drug Administration has approved biosimilar Pyzchiva (ustekinumab-ttwe), ...

Basel, April 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announces that the European Commission (EC) has granted marketing authorization for Pyzchiva®* ...

Sandoz is releasing Pyzchiva (ustekinumab) across Europe. Pyzchiva is approved for treatment of adults with plaque psoriasis, psoriatic arthritis, Crohn’s disease and pediatric plaque psoriasis for ...

Expected to be among first wave of ustekinumab biosimilars to launch in US Basel, July 1, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the US Food and ...

Autoinjector includes unique features to improve comfort, independence and convenience for patients with chronic inflammatory diseases [1-10] Launch strengthens Sandoz biosimilar leadership position ...

Under the terms of the agreement, Organon will obtain exclusive commercial rights to the product in Canada while Samsung Bioepis will maintain full development, manufacturing, and regulatory ...

Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered ...

Sandoz, one of the global leaders in generic and biosimilar medicines, announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe ...